Bruce Shiramizu to Neoplasm, Residual
This is a "connection" page, showing publications Bruce Shiramizu has written about Neoplasm, Residual.
Connection Strength
0.366
-
Shiramizu B, Goldman S, Smith L, Agsalda-Garcia M, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Barth MJ, Mussolin L, Cairo MS. Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report. Br J Haematol. 2015 Aug; 170(3):367-71.
Score: 0.130
-
Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L, Harrison L, Morris E, Gross TG, Sanger W, Perkins S, Cairo MS. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report. Br J Haematol. 2011 Jun; 153(6):758-63.
Score: 0.099
-
Kusao I, Agsalda M, Troelstrup D, Villanueva N, Shiramizu B. Chemotoxicity recovery of mitochondria in non-Hodgkin lymphoma resulting in minimal residual disease. Pediatr Blood Cancer. 2008 Aug; 51(2):193-7.
Score: 0.082
-
Sabesan V, Cairo MS, Lones MA, Perkins SL, Morris E, Sposto R, Van De Ven C, Shiramizu B. Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers. J Pediatr Hematol Oncol. 2003 Feb; 25(2):109-13.
Score: 0.056